Bas G. J. Surewaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bas G. J. Surewaard has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Josefien W. Hommes
Department of Microbiology, Immunology, and Infectious Disease. Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
6 shared publications - Paul Kubes
Department of Physiology and Pharmacology, University of Calgary
3 shared publications - Adrien Guillot
Department of Hepatology & Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany
2 shared publications - Anders Woetmann
LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
2 shared publications - Andreas Willerslev-Olsen
LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
2 shared publications - Bruna Araujo David
Department of Physiology and Pharmacology, University of Calgary, Calgary, Canada
2 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (10) , e1014744
Guardians of the blood: How Kupffer cells control systemic infection
- 30 October 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (10) , e1014744
Open AccessGuardians of the blood: How Kupffer cells control systemic infection
- Open Access
A niche-specific role for ArlRS enables Staphylococcus aureus growth within Kupffer cells
Staphylococcus aureus bloodstream infections cause severe morbidity and mortality despite antibiotic therapy. We previously identified Kupffer cells (KCs) as the primary hepatic macrophages that rapidly clear circulating S. aureus , yet a subset of bacteria survives intracellularly and seeds systemic infection. Here, using spinning-disk intravital and super-resolution microscopy, we show that bacterial two-component system (TCS) signaling is required for intracellular replication within KCs in vivo . A global mutant lacking all non-essential TCSs failed to form intracellular microcolonies, and targeted analysis identified the ArlRS system as specifically required for KC replication. Δ arlRS bacteria remained as single non-replicating organisms within KCs, exhibited reduced dissemination and kidney abscess formation, and showed attenuated virulence with improved host survival. Complementation with arlRS restored the wildtype phenotype. Notably, the intracellular replication defect was not observed in primary or cultured macrophages, indicating that ArlRS-dependent replication is highly niche-specific and not reproduced by conventional in vitro models. Furthermore, restricting the KC reservoir with vancomycin treatment after infection further reduced renal infection by Δ arlRS bacteria. These findings identify ArlRS as a critical regulator of intracellular replication within KCs and establish the KC intracellular reservoir as a key driver of S. aureus pathogenesis and a potential therapeutic target during bloodstream infection.
Open AccessA niche-specific role for ArlRS enables Staphylococcus aureus growth within Kupffer cells
Staphylococcus aureus bloodstream infections cause severe morbidity and mortality despite antibiotic therapy. We previously identified Kupffer cells (KCs) as the primary hepatic macrophages that rapidly clear circulating S. aureus , yet a subset of bacteria survives intracellularly and seeds systemic infection. Here, using spinning-disk intravital and super-resolution microscopy, we show that bacterial two-component system (TCS) signaling is required for intracellular replication within KCs in vivo . A global mutant lacking all non-essential TCSs failed to form intracellular microcolonies, and targeted analysis identified the ArlRS system as specifically required for KC replication. Δ arlRS bacteria remained as single non-replicating organisms within KCs, exhibited reduced dissemination and kidney abscess formation, and showed attenuated virulence with improved host survival. Complementation with arlRS restored the wildtype phenotype. Notably, the intracellular replication defect was not observed in primary or cultured macrophages, indicating that ArlRS-dependent replication is highly niche-specific and not reproduced by conventional in vitro models. Furthermore, restricting the KC reservoir with vancomycin treatment after infection further reduced renal infection by Δ arlRS bacteria. These findings identify ArlRS as a critical regulator of intracellular replication within KCs and establish the KC intracellular reservoir as a key driver of S. aureus pathogenesis and a potential therapeutic target during bloodstream infection.
- Open Access
- 6 April 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (4) , e1014090
Adeno-associated virus delivery of anti-alpha toxin monoclonal antibodies confers protection against Staphylococcus aureus infections
Staphylococcus aureus is a major cause of infections, ranging from mild skin conditions to severe life-threatening systemic diseases. Despite decades of effort, vaccine development has been unsuccessful, highlighting the need for alternative approaches. One promising candidate is MEDI4893 (Suvratoxumab), a monoclonal antibody that neutralizes α-toxin (AT), a key virulence factor with diverse functions including cellular lysis and induction of platelet aggregation during sepsis. MEDI4893 has demonstrated efficacy in various preclinical models of infection and showed encouraging results in a phase IIb clinical trial for ventilator-associated pneumonia. However, as an exogenous antibody, MEDI4893 is limited by its short half-life, high production costs, and restricted availability. To overcome these challenges, we investigated vectored immunoprophylaxis as a novel strategy for long-term protection. This approach uses an adeno-associated viral vector (AAV) to deliver the MEDI4893 gene, enabling sustained in vivo antibody expression. Following AAV-MEDI4893 administration, mice developed high and stable antibody levels in plasma and detectable titers at mucosal surfaces. Using intravital microscopy, we observed that vector-mediated MEDI4893 effectively prevented AT-induced platelet aggregation and microvascular thrombosis, thereby protecting animals from the lethal effects of intravenous toxin challenge. Infection studies confirmed that this protective effect extended to clinically relevant models. In murine pneumonia models, treated mice showed improved survival and reduced sickness behavior despite similar bacterial burdens, while in skin infection models, they were protected from dermal necrosis and exhibited lower bacterial loads. These findings highlight that AT is a major driver of pathology across multiple tissues and that its neutralization can mitigate disease severity. Together, our results demonstrate that AAV-mediated delivery of MEDI4893 provides durable, protective antibody levels and effectively neutralizes AT in vivo . This strategy represents a cost-effective, long-lasting alternative to traditional monoclonal antibody therapy and offers a promising prophylactic approach to mitigate S. aureus infections in the absence of a vaccine.
- 6 April 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (4) , e1014090
Open AccessAdeno-associated virus delivery of anti-alpha toxin monoclonal antibodies confers protection against Staphylococcus aureus infections
Staphylococcus aureus is a major cause of infections, ranging from mild skin conditions to severe life-threatening systemic diseases. Despite decades of effort, vaccine development has been unsuccessful, highlighting the need for alternative approaches. One promising candidate is MEDI4893 (Suvratoxumab), a monoclonal antibody that neutralizes α-toxin (AT), a key virulence factor with diverse functions including cellular lysis and induction of platelet aggregation during sepsis. MEDI4893 has demonstrated efficacy in various preclinical models of infection and showed encouraging results in a phase IIb clinical trial for ventilator-associated pneumonia. However, as an exogenous antibody, MEDI4893 is limited by its short half-life, high production costs, and restricted availability. To overcome these challenges, we investigated vectored immunoprophylaxis as a novel strategy for long-term protection. This approach uses an adeno-associated viral vector (AAV) to deliver the MEDI4893 gene, enabling sustained in vivo antibody expression. Following AAV-MEDI4893 administration, mice developed high and stable antibody levels in plasma and detectable titers at mucosal surfaces. Using intravital microscopy, we observed that vector-mediated MEDI4893 effectively prevented AT-induced platelet aggregation and microvascular thrombosis, thereby protecting animals from the lethal effects of intravenous toxin challenge. Infection studies confirmed that this protective effect extended to clinically relevant models. In murine pneumonia models, treated mice showed improved survival and reduced sickness behavior despite similar bacterial burdens, while in skin infection models, they were protected from dermal necrosis and exhibited lower bacterial loads. These findings highlight that AT is a major driver of pathology across multiple tissues and that its neutralization can mitigate disease severity. Together, our results demonstrate that AAV-mediated delivery of MEDI4893 provides durable, protective antibody levels and effectively neutralizes AT in vivo . This strategy represents a cost-effective, long-lasting alternative to traditional monoclonal antibody therapy and offers a promising prophylactic approach to mitigate S. aureus infections in the absence of a vaccine.
- 1 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (101) , eadq9704
Kupffer cell reverse migration into the liver sinusoids mitigates neonatal sepsis and meningitis
In adults, liver-resident macrophages, or Kupffer cells (KCs), reside in the sinusoids and sterilize circulating blood by capturing rapidly flowing microbes. We developed quantitative intravital imaging of 1-day-old mice combined with transcriptomics, genetic manipulation, and in vivo infection assays to interrogate increased susceptibility of newborns to bloodstream infections. Whereas 1-day-old KCs were better at catching Escherichia coli in vitro, we uncovered a critical 1-week window postpartum when KCs have limited access to blood and must translocate from liver parenchyma into the sinusoids. KC migration was independent of the microbiome but depended on macrophage migration inhibitory factor, its receptor CD74, and the adhesion molecule CD44. On the basis of our findings, we propose a model of progenitor macrophage seeding of the liver sinusoids via a reverse transmigration process from liver parenchyma. These results also illustrate the importance of developing newborn mouse models to understand newborn immunity and disease.
- 1 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (101) , eadq9704
Kupffer cell reverse migration into the liver sinusoids mitigates neonatal sepsis and meningitis
In adults, liver-resident macrophages, or Kupffer cells (KCs), reside in the sinusoids and sterilize circulating blood by capturing rapidly flowing microbes. We developed quantitative intravital imaging of 1-day-old mice combined with transcriptomics, genetic manipulation, and in vivo infection assays to interrogate increased susceptibility of newborns to bloodstream infections. Whereas 1-day-old KCs were better at catching Escherichia coli in vitro, we uncovered a critical 1-week window postpartum when KCs have limited access to blood and must translocate from liver parenchyma into the sinusoids. KC migration was independent of the microbiome but depended on macrophage migration inhibitory factor, its receptor CD74, and the adhesion molecule CD44. On the basis of our findings, we propose a model of progenitor macrophage seeding of the liver sinusoids via a reverse transmigration process from liver parenchyma. These results also illustrate the importance of developing newborn mouse models to understand newborn immunity and disease.
- 1 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (101) , eadn2168
The pore-forming apolipoprotein APOL7C drives phagosomal rupture and antigen cross-presentation by dendritic cells
Conventional dendritic cells (cDCs) generate protective cytotoxic T lymphocyte (CTL) responses against extracellular pathogens and tumors. This is achieved through a process known as cross-presentation (XP), and, despite its biological importance, the mechanism(s) driving XP remains unclear. Here, we show that a cDC-specific pore-forming protein called apolipoprotein L 7C (APOL7C) is up-regulated in response to innate immune stimuli and is recruited to phagosomes. Association of APOL7C with phagosomes led to phagosomal rupture and escape of engulfed antigens to the cytosol, where they could be processed via the endogenous MHC class I antigen processing pathway. Accordingly, mice deficient in APOL7C did not efficiently prime CD8 + T cells in response to immunization with bead-bound and cell-associated antigens. Together, our data indicate the presence of dedicated apolipoproteins that mediate the delivery of phagocytosed proteins to the cytosol of activated cDCs to facilitate XP.
- 1 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (101) , eadn2168
The pore-forming apolipoprotein APOL7C drives phagosomal rupture and antigen cross-presentation by dendritic cells
Conventional dendritic cells (cDCs) generate protective cytotoxic T lymphocyte (CTL) responses against extracellular pathogens and tumors. This is achieved through a process known as cross-presentation (XP), and, despite its biological importance, the mechanism(s) driving XP remains unclear. Here, we show that a cDC-specific pore-forming protein called apolipoprotein L 7C (APOL7C) is up-regulated in response to innate immune stimuli and is recruited to phagosomes. Association of APOL7C with phagosomes led to phagosomal rupture and escape of engulfed antigens to the cytosol, where they could be processed via the endogenous MHC class I antigen processing pathway. Accordingly, mice deficient in APOL7C did not efficiently prime CD8 + T cells in response to immunization with bead-bound and cell-associated antigens. Together, our data indicate the presence of dedicated apolipoproteins that mediate the delivery of phagocytosed proteins to the cytosol of activated cDCs to facilitate XP.
- Open Access
Novel Pentafluorosulfanyl-containing Triclocarban Analogs selectively kill Gram-positive bacteria
The antibacterial and antibiofilm efficacy of our novel pentafluorosulfanyl-containing triclocarban analogs was explored against seven different Gram-positive and Gram-negative indicator strains. After initial screening, they had bactericidal and bacteriostatic activity against Gram-positive bacteria, especially Staphylococcus aureus and MRSA (methicillin–resistant staphylococcus aureus) in a very low concentration. Our results were compared with the most common antibiotic being used (Ciprofloxacin and Gentamycin); the novel components had significantly better antibacterial and antibiofilm activity in lower concentrations in comparison to the antibiotics. For instance, EBP- 59 minimum inhibitory concentration was < 0.0003 mM, while ciprofloxacin 0.08 mM. Further antibacterial activity of novel components was surveyed against 10 clinical antibiotic resistance MRSA isolates. Again, novel components had significantly better antibacterial and antibiofilm activity in comparison with antibiotics. Mechanistic studies have revealed that none of these novel compounds exhibit any effect on the reduced thiol, disrupting iron sulfur clusters, or hydrogen peroxide pathways. Instead, their impact is attributed to the disruption of the Gram-positive bacterial cell membrane. Toxicity and safety testing on tissue cell culture showed promising results for the safety of components to the host.
Open AccessNovel Pentafluorosulfanyl-containing Triclocarban Analogs selectively kill Gram-positive bacteria
The antibacterial and antibiofilm efficacy of our novel pentafluorosulfanyl-containing triclocarban analogs was explored against seven different Gram-positive and Gram-negative indicator strains. After initial screening, they had bactericidal and bacteriostatic activity against Gram-positive bacteria, especially Staphylococcus aureus and MRSA (methicillin–resistant staphylococcus aureus) in a very low concentration. Our results were compared with the most common antibiotic being used (Ciprofloxacin and Gentamycin); the novel components had significantly better antibacterial and antibiofilm activity in lower concentrations in comparison to the antibiotics. For instance, EBP- 59 minimum inhibitory concentration was < 0.0003 mM, while ciprofloxacin 0.08 mM. Further antibacterial activity of novel components was surveyed against 10 clinical antibiotic resistance MRSA isolates. Again, novel components had significantly better antibacterial and antibiofilm activity in comparison with antibiotics. Mechanistic studies have revealed that none of these novel compounds exhibit any effect on the reduced thiol, disrupting iron sulfur clusters, or hydrogen peroxide pathways. Instead, their impact is attributed to the disruption of the Gram-positive bacterial cell membrane. Toxicity and safety testing on tissue cell culture showed promising results for the safety of components to the host.
- 8 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6662) , 1066-+
Kupffer cell–like syncytia replenish resident macrophage function in the fibrotic liver
Kupffer cells (KCs) are localized in liver sinusoids but extend pseudopods to parenchymal cells to maintain their identity and serve as the body’s central bacterial filter. Liver cirrhosis drastically alters vascular architecture, but how KCs adapt is unclear. We used a mouse model of liver fibrosis and human tissue to examine immune adaptation. Fibrosis forced KCs to lose contact with parenchymal cells, down-regulating “KC identity,” which rendered them incapable of clearing bacteria. Commensals stimulated the recruitment of monocytes through CD44 to a spatially distinct vascular compartment. There, recruited monocytes formed large aggregates of multinucleated cells (syncytia) that expressed phenotypical KC markers and displayed enhanced bacterial capture ability. Syncytia formed via CD36 and were observed in human cirrhosis as a possible antimicrobial defense that evolved with fibrosis.
- 8 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6662) , 1066-+
Kupffer cell–like syncytia replenish resident macrophage function in the fibrotic liver
Kupffer cells (KCs) are localized in liver sinusoids but extend pseudopods to parenchymal cells to maintain their identity and serve as the body’s central bacterial filter. Liver cirrhosis drastically alters vascular architecture, but how KCs adapt is unclear. We used a mouse model of liver fibrosis and human tissue to examine immune adaptation. Fibrosis forced KCs to lose contact with parenchymal cells, down-regulating “KC identity,” which rendered them incapable of clearing bacteria. Commensals stimulated the recruitment of monocytes through CD44 to a spatially distinct vascular compartment. There, recruited monocytes formed large aggregates of multinucleated cells (syncytia) that expressed phenotypical KC markers and displayed enhanced bacterial capture ability. Syncytia formed via CD36 and were observed in human cirrhosis as a possible antimicrobial defense that evolved with fibrosis.
- Open Access
- 27 July 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 1804
Intracellular Habitation of Staphylococcus aureus: Molecular Mechanisms and Prospects for Antimicrobial Therapy
Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a global health threat, especially with the continuous development of antibiotic resistance. As an opportunistic pathogen, MRSA infections have a high mortality rate worldwide. Although classically described as an extracellular pathogen, many studies have shown over the past decades that MRSA also has an intracellular aspect to its infectious cycle, which has been observed in vitro in both non-professional as well as professional phagocytes. In vivo, MRSA has been shown to establish an intracellular niche in liver Kupffer cells upon bloodstream infection. The staphylococci have evolved various evasion strategies to survive the antimicrobial environment of phagolysosomes and use these compartments to hide from immune cells and antibiotics. Ultimately, the host cells get overwhelmed by replicating bacteria, leading to cell lysis and bacterial dissemination. In this review, we describe the different intracellular aspects of MRSA infection and briefly mention S. aureus evasion strategies. We discuss how this intracellular niche of bacteria may assist in antibiotic tolerance development, and lastly, we describe various new antibacterial strategies that target the intracellular bacterial niche.
- 27 July 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 1804
Open AccessIntracellular Habitation of Staphylococcus aureus: Molecular Mechanisms and Prospects for Antimicrobial Therapy
Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a global health threat, especially with the continuous development of antibiotic resistance. As an opportunistic pathogen, MRSA infections have a high mortality rate worldwide. Although classically described as an extracellular pathogen, many studies have shown over the past decades that MRSA also has an intracellular aspect to its infectious cycle, which has been observed in vitro in both non-professional as well as professional phagocytes. In vivo, MRSA has been shown to establish an intracellular niche in liver Kupffer cells upon bloodstream infection. The staphylococci have evolved various evasion strategies to survive the antimicrobial environment of phagolysosomes and use these compartments to hide from immune cells and antibiotics. Ultimately, the host cells get overwhelmed by replicating bacteria, leading to cell lysis and bacterial dissemination. In this review, we describe the different intracellular aspects of MRSA infection and briefly mention S. aureus evasion strategies. We discuss how this intracellular niche of bacteria may assist in antibiotic tolerance development, and lastly, we describe various new antibacterial strategies that target the intracellular bacterial niche.
- Open Access
- 25 January 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (2)
A functionally distinct neutrophil landscape in severe COVID-19 reveals opportunities for adjunctive therapies
Acute respiratory distress syndrome (ARDS) is a life-threatening syndrome, constituted by respiratory failure and diffuse alveolar damage that results from dysregulated local and systemic immune activation, causing pulmonary vascular, parenchymal, and alveolar damage. SARS-CoV-2 infection has become the dominant cause of ARDS worldwide, and emerging evidence implicates neutrophils and their cytotoxic arsenal of effector functions as central drivers of immune-mediated lung injury in COVID-19 ARDS. However, key outstanding questions are whether COVID-19 drives a unique program of neutrophil activation or effector functions that contribute to the severe pathogenesis of this pandemic illness and whether this unique neutrophil response can be targeted to attenuate disease. Using a combination of high-dimensional single-cell analysis and ex vivo functional assays of neutrophils from patients with COVID-19 ARDS, compared with those with non-COVID ARDS (caused by bacterial pneumonia), we identified a functionally distinct landscape of neutrophil activation in COVID-19 ARDS that was intrinsically programmed during SARS-CoV-2 infection. Furthermore, neutrophils in COVID-19 ARDS were functionally primed to produce high amounts of neutrophil extracellular traps. Surprisingly, this unique pathological program of neutrophil priming escaped conventional therapy with dexamethasone, thereby revealing a promising target for adjunctive immunotherapy in severe COVID-19.
- 25 January 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (2)
Open AccessA functionally distinct neutrophil landscape in severe COVID-19 reveals opportunities for adjunctive therapies
Acute respiratory distress syndrome (ARDS) is a life-threatening syndrome, constituted by respiratory failure and diffuse alveolar damage that results from dysregulated local and systemic immune activation, causing pulmonary vascular, parenchymal, and alveolar damage. SARS-CoV-2 infection has become the dominant cause of ARDS worldwide, and emerging evidence implicates neutrophils and their cytotoxic arsenal of effector functions as central drivers of immune-mediated lung injury in COVID-19 ARDS. However, key outstanding questions are whether COVID-19 drives a unique program of neutrophil activation or effector functions that contribute to the severe pathogenesis of this pandemic illness and whether this unique neutrophil response can be targeted to attenuate disease. Using a combination of high-dimensional single-cell analysis and ex vivo functional assays of neutrophils from patients with COVID-19 ARDS, compared with those with non-COVID ARDS (caused by bacterial pneumonia), we identified a functionally distinct landscape of neutrophil activation in COVID-19 ARDS that was intrinsically programmed during SARS-CoV-2 infection. Furthermore, neutrophils in COVID-19 ARDS were functionally primed to produce high amounts of neutrophil extracellular traps. Surprisingly, this unique pathological program of neutrophil priming escaped conventional therapy with dexamethasone, thereby revealing a promising target for adjunctive immunotherapy in severe COVID-19.
- Open Access
- 16 September 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (9) , e1009880
Commensal bacteria augment Staphylococcus aureus infection by inactivation of phagocyte-derived reactive oxygen species
Staphylococcus aureus is a human commensal organism and opportunist pathogen, causing potentially fatal disease. The presence of non-pathogenic microflora or their components, at the point of infection, dramatically increases S. aureus pathogenicity, a process termed augmentation. Augmentation is associated with macrophage interaction but by a hitherto unknown mechanism. Here, we demonstrate a breadth of cross-kingdom microorganisms can augment S. aureus disease and that pathogenesis of Enterococcus faecalis can also be augmented. Co-administration of augmenting material also forms an efficacious vaccine model for S. aureus. In vitro, augmenting material protects S. aureus directly from reactive oxygen species (ROS), which correlates with in vivo studies where augmentation restores full virulence to the ROS-susceptible, attenuated mutant katA ahpC. At the cellular level, augmentation increases bacterial survival within macrophages via amelioration of ROS, leading to proliferation and escape. We have defined the molecular basis for augmentation that represents an important aspect of the initiation of infection.
- 16 September 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (9) , e1009880
Open AccessCommensal bacteria augment Staphylococcus aureus infection by inactivation of phagocyte-derived reactive oxygen species
Staphylococcus aureus is a human commensal organism and opportunist pathogen, causing potentially fatal disease. The presence of non-pathogenic microflora or their components, at the point of infection, dramatically increases S. aureus pathogenicity, a process termed augmentation. Augmentation is associated with macrophage interaction but by a hitherto unknown mechanism. Here, we demonstrate a breadth of cross-kingdom microorganisms can augment S. aureus disease and that pathogenesis of Enterococcus faecalis can also be augmented. Co-administration of augmenting material also forms an efficacious vaccine model for S. aureus. In vitro, augmenting material protects S. aureus directly from reactive oxygen species (ROS), which correlates with in vivo studies where augmentation restores full virulence to the ROS-susceptible, attenuated mutant katA ahpC. At the cellular level, augmentation increases bacterial survival within macrophages via amelioration of ROS, leading to proliferation and escape. We have defined the molecular basis for augmentation that represents an important aspect of the initiation of infection.